Evommune Inc. (EVMN) vs X4 Pharmaceuticals, Inc. (XFOR)

Evommune Inc. and X4 Pharmaceuticals, Inc. are both Biotechnology companies. Evommune Inc. and X4 Pharmaceuticals, Inc. are of similar size ($309.9M and $297.4M). Evommune Inc. has the higher net margin (0.00% vs −568.8%) and the higher return on invested capital (−82.5% vs −226.6%). Across the 13 metrics below, Evommune Inc. leads on 9 and X4 Pharmaceuticals, Inc. on 4.

Valuation

Metric EVMN XFOR Biotechnology median
P/E n/m n/m 7.88
P/S n/m 24.00 11.47
P/B 1.10 2.45 2.52
Price to free cash flow n/m 23.86 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 15.77 10.73
Earnings yield (130.22%) (39.87%) (28.84%)
Free cash flow yield (24.39%) 4.19% (23.03%)

Profitability

Metric EVMN XFOR Biotechnology median
Gross margin — 81.51% 65.16%
Operating margin 0.00% (554.71%) 0.00%
Net margin 0.00% (568.80%) 0.00%
Free cash flow margin 0.00% (559.95%) 0.00%
Return on equity (141.99%) (113.08%) (57.72%)
Return on assets (62.71%) (50.32%) (49.22%)
Return on invested capital (82.46%) (226.62%) 0.00%

Growth

Metric EVMN XFOR Biotechnology median
Revenue growth (TTM) — (51.65%) 5.64%
EPS growth (last fiscal year) 75.23% 67.23% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric EVMN XFOR Biotechnology median
Debt to equity 0.00 0.49 0.00
Current ratio 11.68 11.30 4.73
Net debt to EBITDA 1.87 2.06 0.96

Dividend

Metric EVMN XFOR Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric EVMN XFOR Biotechnology median
Market cap 309.93m 297.44m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack